MA56394A - Anticorps anti-angpt2 - Google Patents

Anticorps anti-angpt2

Info

Publication number: MA56394A
Authority: MA; Morocco
Prior art keywords: angpt2 antibodies; angpt2; antibodies
Prior art date: 2019-06-27

Application number

MA056394A

Other languages

English (en)

Inventor

Thierry Bouyssou

Michael Dziegelewski

Ryan Michael Fryer

Pankaj Gupta

Paul Nicklin

Chao Zheng

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-06-27

Filing date

2020-06-25

Publication date

2022-05-04

2020-06-25 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2022-05-04 Publication of MA56394A publication Critical patent/MA56394A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Tropical Medicine & Parasitology (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Mycology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA056394A 2019-06-27 2020-06-25 Anticorps anti-angpt2 MA56394A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201962867253P	2019-06-27	2019-06-27
US202063013022P	2020-04-21	2020-04-21

Publications (1)

Publication Number	Publication Date
MA56394A true MA56394A (fr)	2022-05-04

Family

ID=71662321

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA056394A MA56394A (fr)	2019-06-27	2020-06-25	Anticorps anti-angpt2

Country Status (21)

Country	Link
US (2)	US11396539B2 (fr)
EP (1)	EP3990489A1 (fr)
JP (1)	JP7649756B2 (fr)
KR (1)	KR20220028032A (fr)
CN (1)	CN114080396B (fr)
AU (1)	AU2020308569A1 (fr)
BR (1)	BR112021024176A2 (fr)
CA (1)	CA3140071A1 (fr)
CL (1)	CL2021003367A1 (fr)
CO (1)	CO2021017414A2 (fr)
CR (1)	CR20210683A (fr)
EC (1)	ECSP22004680A (fr)
IL (1)	IL289160A (fr)
JO (1)	JOP20210339A1 (fr)
MA (1)	MA56394A (fr)
MX (1)	MX2021015743A (fr)
PE (1)	PE20220809A1 (fr)
PH (1)	PH12021553117A1 (fr)
SA (1)	SA521431223B1 (fr)
TW (1)	TWI877179B (fr)
WO (1)	WO2020264065A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI877179B (zh) *	2019-06-27	2025-03-21	德商百靈佳殷格翰國際股份有限公司	抗-angpt2抗體

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE266710C (fr)
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4275149A (en)	1978-11-24	1981-06-23	Syva Company	Macromolecular environment control in specific receptor assays
US4318980A (en)	1978-04-10	1982-03-09	Miles Laboratories, Inc.	Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja)	1979-07-11	1985-06-05	味の素株式会社	代用血液
US4419446A (en)	1980-12-31	1983-12-06	The United States Of America As Represented By The Department Of Health And Human Services	Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en)	1981-08-31	1986-03-14	Genentech Inc	Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en)	1981-10-30	1987-02-03	Nippon Chemiphar Company, Ltd.	Plasminogen activator derivatives
US4434173A (en)	1982-08-23	1984-02-28	Pfizer Inc.	Bis-esters of 4,5-di(hydroxymethyl)-2-oxo-1,3-dioxole as antibacterial agents
US4601978A (en)	1982-11-24	1986-07-22	The Regents Of The University Of California	Mammalian metallothionein promoter system
US4560655A (en)	1982-12-16	1985-12-24	Immunex Corporation	Serum-free cell culture medium and process for making same
US4657866A (en)	1982-12-21	1987-04-14	Sudhir Kumar	Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
DD266710A3 (de)	1983-06-06	1989-04-12	Ve Forschungszentrum Biotechnologie	Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en)	1983-10-07	1988-08-30	Columbia University In The City Of New York	Protein-free culture medium
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en)	1984-04-20	1990-10-23	Genentech, Inc.	Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en)	1984-10-30	1989-11-07	Phillips Petroleum Company	Transformation of yeasts of the genus pichia
US4737456A (en)	1985-05-09	1988-04-12	Syntex (U.S.A.) Inc.	Reducing interference in ligand-receptor binding assays
DE3675588D1 (de)	1985-06-19	1990-12-20	Ajinomoto Kk	Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8516415D0 (en)	1985-06-28	1985-07-31	Celltech Ltd	Culture of animal cells
US4927762A (en)	1986-04-01	1990-05-22	Cell Enterprises, Inc.	Cell culture medium with antioxidant
GB8610600D0 (en)	1986-04-30	1986-06-04	Novo Industri As	Transformation of trichoderma
US4791192A (en)	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
DE68925971T2 (de)	1988-09-23	1996-09-05	Cetus Oncology Corp	Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr)	1989-04-28	1991-08-30	Transgene Sa	Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5122469A (en)	1990-10-03	1992-06-16	Genentech, Inc.	Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1994004679A1 (fr)	1991-06-14	1994-03-03	Genentech, Inc.	Procede pour fabriquer des anticorps humanises
ATE255131T1 (de)	1991-06-14	2003-12-15	Genentech Inc	Humanisierter heregulin antikörper
DE69303494T2 (de)	1992-11-13	1997-01-16	Idec Pharma Corp	Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US6096871A (en)	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en)	1996-11-27	2000-03-14	Genentech, Inc.	Humanized anti-CD11a antibodies
US5888809A (en)	1997-05-01	1999-03-30	Icos Corporation	Hamster EF-1α transcriptional regulatory DNA
US6455035B1 (en) *	1999-03-26	2002-09-24	Regeneron Pharmaceuticals, Inc.	Angiopoietins and methods of use thereof
ES2371083T3 (es) *	2004-12-21	2011-12-27	Medimmune Limited	Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos.
US8507656B2 (en) *	2008-01-28	2013-08-13	Medimmune Limited	Stabilized angiopoietin-2 antibodies and uses thereof
US8133979B2 (en)	2008-12-16	2012-03-13	Hoffmann-La Roche Inc.	Antibodies against human angiopoietin 2
JO3182B1 (ar) *	2009-07-29	2018-03-08	Regeneron Pharma	مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20110227286A1 (en) *	2010-03-18	2011-09-22	Davies Janet L	Board Game and Method of Playing the Same
US9575073B2 (en) *	2011-10-10	2017-02-21	Rutgers, The State University Of New Jersey	Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
WO2013134516A1 (fr) *	2012-03-08	2013-09-12	Medimmune, Llc	Procédés de traitement par des anticorps anti-angiopoïétine-2
US9828422B2 (en) *	2013-07-29	2017-11-28	Samsung Electronics Co., Ltd.	Anti-Ang2 antibody
WO2015091655A1 (fr) *	2013-12-20	2015-06-25	F. Hoffmann-La Roche Ag	Polythérapie avec un anticorps anti-ang 2 et un agoniste cd40
AR100270A1 (es) *	2014-05-19	2016-09-21	Lilly Co Eli	Anticuerpos ang2
HRP20210124T1 (hr) *	2014-11-19	2021-03-19	Axon Neuroscience Se	Humanizirana tau antitijela u alzheimerovoj bolesti
KR20230082055A (ko) *	2016-06-17	2023-06-08	마젠타 테라퓨틱스 인코포레이티드	세포의 고갈을 위한 조성물 및 방법
CA3040893A1 (fr) *	2016-10-21	2018-04-26	Adimab, Llc	Anticorps anti-virus respiratoire syncytial, et leurs procedes de generation et d'utilisation
JP6496095B1 (ja) *	2017-09-29	2019-04-03	中外製薬株式会社	血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）補因子機能代替活性を有する多重特異性抗原結合分子および当該分子を有効成分として含有する薬学的製剤
TWI877179B (zh) *	2019-06-27	2025-03-21	德商百靈佳殷格翰國際股份有限公司	抗-angpt2抗體

2020
- 2020-06-24 TW TW109121573A patent/TWI877179B/zh active
- 2020-06-25 PH PH1/2021/553117A patent/PH12021553117A1/en unknown
- 2020-06-25 KR KR1020227003085A patent/KR20220028032A/ko active Pending
- 2020-06-25 EP EP20742550.5A patent/EP3990489A1/fr active Pending
- 2020-06-25 AU AU2020308569A patent/AU2020308569A1/en not_active Abandoned
- 2020-06-25 CR CR20210683A patent/CR20210683A/es unknown
- 2020-06-25 WO PCT/US2020/039477 patent/WO2020264065A1/fr not_active Ceased
- 2020-06-25 CN CN202080047312.1A patent/CN114080396B/zh active Active
- 2020-06-25 MA MA056394A patent/MA56394A/fr unknown
- 2020-06-25 US US16/911,419 patent/US11396539B2/en active Active
- 2020-06-25 JP JP2021576151A patent/JP7649756B2/ja active Active
- 2020-06-25 CA CA3140071A patent/CA3140071A1/fr active Pending
- 2020-06-25 BR BR112021024176A patent/BR112021024176A2/pt unknown
- 2020-06-25 PE PE2021002220A patent/PE20220809A1/es unknown
- 2020-06-25 MX MX2021015743A patent/MX2021015743A/es unknown
2021
- 2021-12-16 CL CL2021003367A patent/CL2021003367A1/es unknown
- 2021-12-17 CO CONC2021/0017414A patent/CO2021017414A2/es unknown
- 2021-12-20 IL IL289160A patent/IL289160A/en unknown
- 2021-12-27 SA SA521431223A patent/SA521431223B1/ar unknown
- 2021-12-27 JO JOP/2021/0339A patent/JOP20210339A1/ar unknown
2022
- 2022-01-19 EC ECSENADI20224680A patent/ECSP22004680A/es unknown
- 2022-06-17 US US17/842,904 patent/US20220363743A1/en not_active Abandoned

Also Published As

Publication number	Publication date
TWI877179B (zh)	2025-03-21
WO2020264065A1 (fr)	2020-12-30
JP7649756B2 (ja)	2025-03-21
CO2021017414A2 (es)	2022-01-17
IL289160A (en)	2022-02-01
MX2021015743A (es)	2022-01-27
US11396539B2 (en)	2022-07-26
CR20210683A (es)	2022-02-23
SA521431223B1 (ar)	2024-04-21
US20200407435A1 (en)	2020-12-31
PH12021553117A1 (en)	2022-07-25
PE20220809A1 (es)	2022-05-20
KR20220028032A (ko)	2022-03-08
BR112021024176A2 (pt)	2022-03-22
CA3140071A1 (fr)	2020-12-30
JP2022538062A (ja)	2022-08-31
CN114080396B (zh)	2024-05-17
JOP20210339A1 (ar)	2023-01-30
CN114080396A (zh)	2022-02-22
CL2021003367A1 (es)	2022-10-07
ECSP22004680A (es)	2022-02-25
AU2020308569A1 (en)	2021-12-02
TW202115112A (zh)	2021-04-16
EP3990489A1 (fr)	2022-05-04
US20220363743A1 (en)	2022-11-17

Publication	Publication Date	Title
MA52884A (fr)	2021-04-21	Anticorps anti-il-11
MA53434A (fr)	2021-12-01	Anticorps anti-tigit
EP3903817A4 (fr)	2022-08-17	Nouvel anticorps anti-ccr8
EP3784699A4 (fr)	2022-04-13	Anticorps anti-tl1a optimisés
EP3883970A4 (fr)	2022-03-30	Anticorps anti-b7-h3
MA52742A (fr)	2021-04-14	Anticorps bispécifiques dll3-cd3
EP3836960A4 (fr)	2022-05-11	Anticorps cd47 thérapeutiques
MA52212A (fr)	2021-02-17	Anticorps multivalent
MA49034A (fr)	2020-02-12	Anticorps anti-lag3
MA47694A (fr)	2021-05-19	Anticorps anti-tigit
MA47268A (fr)	2019-11-20	Anticorps anti-gpc3
MA55600A (fr)	2022-02-16	Anticorps anti-ige
MA52152A (fr)	2021-01-20	Anticorps
EP3752536A4 (fr)	2022-05-11	Anticorps anti-her2
EP3995582A4 (fr)	2023-01-18	Anticorps anti-epha4
EP4081547A4 (fr)	2024-02-21	Nouveaux anticorps anti-fgfr2b
EP3831851A4 (fr)	2022-04-27	Anticorps anti-btla
EP3617231A4 (fr)	2021-04-07	Anticorps anti-gpc-1
EP4271712A4 (fr)	2025-05-07	Anticorps anti-hvem
MA51134A (fr)	2021-03-24	Anticorps anti-alpha-synucléine
MA55705A (fr)	2022-02-23	Anticorps bispécifiques
MA51135A (fr)	2021-03-24	Anticorps anti-alpha-synucléine
EP3852779A4 (fr)	2022-06-08	Anticorps anti-klrg1
MA50654A (fr)	2020-08-05	Anticorps anti-pacap
MA49257A (fr)	2020-04-15	Anticorps anti-trkb